ArticleOncotarget2018

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.

Chintan Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.